NXTC - NextCure Short-Term Debt to Capital

Symbol and logo of brand NextCure Corp (NXTC)

The business security of NextCure, Inc. (NXTC) is ensured by exclusive protein target discovery rights and influence within US oncology, which is confirmed by the stock price action with the indicator 0.02. NextCure, Inc. (NXTC) focuses on discovering new therapeutic pathways to combat solid tumors. Current success depends on test results and effective expense management, which is partially offset by grants received.

Current Liabilities to Capital: NextCure Corp (NXTC) for 07/04/2022 - 10/29/2026

Summary analytical data breakdowns for nextcure.com (NXTC)

- stock value and consensus price forecast:
Price Chart NextCure Corp|NXTC - Broker Consensus Forecast
- market capitalization statistics:
Market Capitalization NextCure Inc|NXTC - Real Price to Acquire Entire Company
- book capitalization information:
Net Assets per Single Share NextCure|NXTC - Total Stockholders' Equity|Market Value to Book Value Ratio nextcure.com|NXTC - Aggregate Company Assets
- issuer credit burden and liquidity indicators:
Debt to Equity NextCure, Inc.|NXTC - Long-Term Liabilities to Capital|Short-Term Debt to Capital NextCure|NXTC - Company Total Indebtedness|Debt to Book Value NextCure Inc|NXTC - Long-Term Debt|Company Current Liabilities NextCure|Quick Ratio nextcure.com
- company profitability and valuation multiples indicators:
NXTC - Net Financial Result
Initial company analysis:NextCure Corp NXTC
Signature product of nextcure.com

This indicator measures the proportion of short-term liabilities relative to equity, allowing for an assessment of liquidity and default risk during sharp market turmoil. By analyzing the ratio of short-term debt to equity, an investor determines the financial stability of NextCure, Inc. (NXTC), where a low debt load is critical to sustaining multi-year developments of immuno-oncology platforms and minimizing clinical pipeline risks.

Competitors of NextCure, Inc. (NXTC)

Short-Term Debt to Equity ImmunityBio Corp (IBRX)|Immunocore Corp - Short-Term Debt to Capital Ratio|Short-Term Debt to Capital JANX (Janux Therapeutics)|RCUS - Short-Term Debt to Equity Ratio|ZYME - Short-Term Debt to Equity|Current Liabilities to Capital Tango Therapeutics Inc|Iovance (IOVA) - Short-Term Debt to Equity|IMTX (Immatics Biotechnologies) - Short-Term Debt to Equity|Short-Term Debt to Equity Xencor, Inc.|Current Liabilities to Capital compasstherapeutics.com CMPX|Short-Term Debt to Capital REPL|Lyell (LYEL) - Short-Term Indebtedness to Equity|Innate Pharma, S.A. - Short-Term Debt to Equity Ratio|Pyxis Oncology Inc. (PYXS) - Current Liabilities to Capital|CGEN: Short-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital IOBT (iobiotech.com)|STRO: Short-Term Debt to Capital|INKT - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Werewolf Therapeutics Inc.|Short-Term Debt to Equity Ratio Immix (IMMX)|Short-Term Debt to Equity ALX Oncology (ALXO)|Short-Term Debt to Equity Ratio Cue Biopharma Inc. CUE|PDS Biotechnology Corporation - Short-Term Debt to Equity Ratio|Short-Term Debt to Capital Sonnet BioTherapeutics Holdings, Inc. SONN|MAIA - Short-Term Debt to Equity|LIMN (Liminatus) - Short-Term Debt to Capital Ratio|lavatherapeutics.com (LVTX) - Short-Term Debt to Equity|Current Liabilities to Capital Leap Therapeutics (LPTX)|Short-Term Debt to Equity Ratio INTS|SNSE - Short-Term Indebtedness to Equity|Short-Term Debt to Equity Ratio TOVX (Synthetic Biologics)|Short-Term Loans to Capital Ratio GRTS|Short-Term Debt to Capital KA (Kineta, Inc.)|Ratio of Short-Term Indebtedness to Capital NEXI|Turnstone Biologics Corporation - Short-Term Debt to Capital|Current Liabilities to Capital Vaccinex Inc.|Harpoon Tx (HARP) - Short-Term Debt to Equity